RS51698B - Pyrrolopyrimidines as protein kinase inhibitors - Google Patents

Pyrrolopyrimidines as protein kinase inhibitors

Info

Publication number
RS51698B
RS51698B YU99203A YUP99203A RS51698B RS 51698 B RS51698 B RS 51698B YU 99203 A YU99203 A YU 99203A YU P99203 A YUP99203 A YU P99203A RS 51698 B RS51698 B RS 51698B
Authority
RS
Serbia
Prior art keywords
ny1y2
ny3y4
heteroaryl
aryl
cycloalkyl
Prior art date
Application number
YU99203A
Other languages
Serbian (sr)
Inventor
Shelley Amendola
Chris Edlin
Paul Joseph Cox
Tahir Nadeem Majid
Stephanie Daniele Deprets
Brian Leslie Pedgrift
Frank Halley
Michael Edwards
Bernard Baudoin
Lain Mcfarlane Mclay
Davis John Aldous
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Priority to MEP-193/08A priority Critical patent/MEP19308A/en
Publication of RS99203A publication Critical patent/RS99203A/en
Publication of RS51698B publication Critical patent/RS51698B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Jedinjenje formulegdeR1 predstavlja vodonik, -C(=O)-NY1Y2, -C(=O)-OR5, -SO2-NY1Y2, -SO2-R7, -C(=O)R7, iliR1 predstavlja alkenil, alkeniloksi, alkil, alkynil, aril, heteroaril, heterocikloalkil, cikloalkil ili cikloalkilalkil, svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cikloalkil, cijano, halo, heteroaril, heterocikloalkil, -CHO, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4,-N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -OR7, -C(=O)-R7, hidroksi, alkoksi i karboksi;R2 predstavalja jednu ili više grupa odabranih od vodonika, acil, alkilenedioksi, alkenil, alkeniloksi, alkinil, aril, cijano, halo, hidroksi, heteroaril, heterocikloalkil, nitro,R4, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, N(R6)-C(=O)-NY3Y4, -N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -SO2-NY1Y2 i -ZR4;R3 predstavlja H, cijano, halo, hidroksi, nitro, R4, NY1Y2, -ZR4, -C(=O)-OR5, C(=O)-R7, -C(=O)-NY1Y2, -N(R8)-C(=O)-R4, -N(R8)-C(=O)NY1Y2; -N(R8)-C(=O)-OR5, -SO2-NY3Y4 ili -N(R8)-SO2-R7, iliR3 predstavlja aril, heteroaril, alkenil ili alkinil, svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cijano, halo, hidroksi, heteroaril, heterocikloalkil, nitro,-C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7, -N(R6)-C(=O)-NY3Y4,-N(R6)-C(=O)-OR7, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -SO2-NY1Y2 i -ZR4;R4 predstavlja alkil, cikloalkil ili cikloalklalkil svaki po izboru supstituisan jednom ili više grupa odabranih od aril, cikloalkil, cijano, halo, heteroaril, heterocikloalkil, hidroksi, -CHO, -C(=O)-NY1Y2, -C(=O)-OR5, -NY1Y2, -N(R6)-C(=O)-R7,-N(R6)-C(=O)-NY3Y4,-N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4, -OR7 i -C(=O)-R7pri čemu je u R4 je po izboru umetnuta grupa odabranaod O, S(O)n, i NR6R5 predstavlja vodonik, alkil, alkenil, aril, arilalkil, heteroaril ili heteroarilalkil;R6 predstavlja vodonik ili niži alkil;R7 predstavlja alkil, aril, arilalkil, cikloalkil, cikoalkilalkil, heteroaril, heteroarilalkil, heterocikloalkil ili heterocikloalkilalkil;R8 predstavlja vodonik ili niži alkil;Y1 i Y2 su nezavisno vodonik, alkenil, aril, cikloalkil, heteroaril ili alkil po izboru supstituisan jednom ili više grupa odabranih od aril, halo, heteroaril, hidroksi, -C(=O)-NY3Y4, -C(=O)-OR5, -NY3Y4, -N(R6)-C(=O)- R7, -N(R6)-C(=O)-NY3Y4, -N(R6)-SO2-R7, -N(R6)-SO2-NY3Y4 i -OR7; or the grupa – NY1Y2 može da formira ciklični amin;Y3 i Y4 su nezavinso vodonik, alkenil, alkil, aril, arilalkil, cikloalkil, heteroaril ili heteroarilalkil; ili -NY3Y4 grupa može da formira ciklični amin;Z predstavlja O ili S(O)n; n je nula ili broj 1 ili 2; iliN-oksid, bioizoster kiseline, farmaceutski prihvatljiva so ili solvat datog jedinjenja; ili N-oksid, ili kiseli bioizostar date soli ili solvata,pri čemu alkenil je alifatična ugljovodonična grupa koja sadrži ugljenik-ugljenik dvostruku vezu i prav ili razgranat lanac sa 2 do 15 atoma ugljenika,pri čemThe compound of the formula R1 represents hydrogen, -C (= O) -NY1Y2, -C (= O) -OR5, -SO2-NY1Y2, -SO2-R7, -C (= O) R7, or R1 represents alkenyl, alkenyloxy, alkyl, alkynyl , aryl, heteroaryl, heterocycloalkyl, cycloalkyl or cycloalkylalkyl, each optionally substituted by one or more groups selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO, -C (= O) -NY1Y2, -C (= O ) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -OR7, -C (= O) -R7, hydroxy, alkoxy and carboxy; R2 represents one or more groups selected from hydrogen, acyl, alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy , heteroaryl, heterocycloalkyl, nitro, R4, -C (= O) -NY1Y2, -C (= O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, N (R6) -C (= O) -NY3Y4, -N (R6) -C (= O) -OR7, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -SO2-NY1Y2 and -ZR4; R3 represents H, cyano, halo, hydroxy, nitro, R4, NY1Y2, -ZR4, -C (= O) -OR5, C (= O) -R7, -C (= O) -NY1Y2, -N (R8) - C (= O) -R4, -N (R8) -C (= O) NY1Y2; -N (R8) -C (= O) -OR5, -SO2-NY3Y4 or -N (R8) -SO2-R7, or R3 represents aryl, heteroaryl, alkenyl or alkynyl, each optionally substituted by one or more groups selected from aryl , cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C (= O) -NY1Y2, -C (= O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -C (= O) -OR7, -N (R6) -SO2-R7, -N (R6) -SO2-NY3Y4, -SO2-NY1Y2 and -ZR4; R4 represents alkyl, cycloalkyl or cycloalkylalkyl each optionally substituted by one or more groups selected from aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, hydroxy, -CHO, -C (= O) -NY1Y2, -C ( = O) -OR5, -NY1Y2, -N (R6) -C (= O) -R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2-R7, -N ( R6) -SO2-NY3Y4, -OR7 and -C (= O) -R7 wherein R4 is an optionally inserted group selected from O, S (O) n, and NR6R5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R6 represents hydrogen or lower alkyl; R7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 represents hydrogen or lower alkyl; Y1 and Y2 are independently hydrogen, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by one or more groups selected from aryl, halo, heteroaryl, hydroxy, -C (= O) - NY3Y4, -C (= O) -OR5, -NY3Y4, -N (R6) -C (= O) - R7, -N (R6) -C (= O) -NY3Y4, -N (R6) -SO2- R7, -N (R6) -SO2-NY3Y4 and -OR7; or the group - NY1Y2 may form a cyclic amine; Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or a -NY3Y4 group may form a cyclic amine; Z represents O or S (O) n; n is zero or number 1 or 2; or N-oxide, an acid bioisoster, a pharmaceutically acceptable salt or solvate of a given compound; or N-oxide, or an acidic bioisomer of a given salt or solvate, wherein the alkenyl is an aliphatic hydrocarbon group containing a carbon-carbon double bond and a straight or branched chain of 2 to 15 carbon atoms, wherein

YU99203A 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors RS51698B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MEP-193/08A MEP19308A (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0115393.1A GB0115393D0 (en) 2001-06-23 2001-06-23 Chemical compounds
US30167801P 2001-06-28 2001-06-28
PCT/GB2002/002835 WO2003000695A1 (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Publications (2)

Publication Number Publication Date
RS99203A RS99203A (en) 2006-12-15
RS51698B true RS51698B (en) 2011-10-31

Family

ID=9917225

Family Applications (1)

Application Number Title Priority Date Filing Date
YU99203A RS51698B (en) 2001-06-23 2002-06-21 Pyrrolopyrimidines as protein kinase inhibitors

Country Status (22)

Country Link
EP (1) EP1404676A1 (en)
JP (1) JP4344607B2 (en)
CN (1) CN1294135C (en)
AU (1) AU2002314325B8 (en)
BR (1) BR0210652A (en)
CA (1) CA2451932C (en)
CZ (1) CZ20033443A3 (en)
EA (1) EA007415B1 (en)
EC (1) ECSP034922A (en)
EE (1) EE05432B1 (en)
GB (1) GB0115393D0 (en)
HU (1) HUP0400300A3 (en)
ME (1) MEP19308A (en)
NZ (1) NZ529766A (en)
OA (1) OA12632A (en)
PL (1) PL374096A1 (en)
RS (1) RS51698B (en)
SK (1) SK15882003A3 (en)
TN (1) TNSN03144A1 (en)
TR (1) TR200302242T2 (en)
UA (1) UA76760C2 (en)
WO (1) WO2003000695A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
CN103169708B (en) 2002-07-29 2018-02-02 里格尔药品股份有限公司 The method that autoimmune disease is treated or prevented with 2,4 pyrimidinediamine compounds
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689407A1 (en) * 2003-11-25 2006-08-16 Pfizer Products Inc. Method of treatment of atherosclerosis
EP1763524A1 (en) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
FR2878849B1 (en) 2004-12-06 2008-09-12 Aventis Pharma Sa SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN103214483B (en) 2005-12-13 2014-12-17 因塞特公司 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2009211004C1 (en) 2008-01-11 2013-08-01 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
KR20110017431A (en) 2008-06-10 2011-02-21 아보트 러보러터리즈 Novel tricyclic compounds
DK2432472T3 (en) 2009-05-22 2019-11-18 Incyte Holdings Corp 3- [4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL] OCTAN OR HEPTAN NITRIL AS JAK INHIBITORS
BRPI1012159B1 (en) 2009-05-22 2022-01-25 Incyte Holdings Corporation Compounds derived from n-(hetero)aryl-pyrrolidine of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors, compositions pharmaceuticals comprising said compounds and uses thereof
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
CR20170159A (en) 2009-12-01 2017-06-26 Abbvie Inc NEW TRICYCLIC COMPOUNDS
KR102283091B1 (en) 2010-03-10 2021-07-30 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
AR083933A1 (en) 2010-11-19 2013-04-10 Incyte Corp PIRROLOPIRIDINE AND PIRROLOPIRIMIDINE DERIVATIVES REPLACED WITH CYCLOBUTILO AS JAK INHIBITORS
CN102093364B (en) * 2011-01-07 2015-01-28 北京赛林泰医药技术有限公司 2,4-diamido-6,7-dihydro-5H-pyrrolo [2,3] pyrimidine derivative as focal adhesion kinase/pyruvate kinase 2 (FAK/Pyk2) inhibitor
CN103476776B (en) * 2011-01-07 2016-09-28 北京赛林泰医药技术有限公司 2,4-diaminourea-6,7-dihydro-5H-pyrrolo-[2,3] pyrimidine derivatives as FAK/Pyk2 inhibitor
CN103797010B (en) 2011-06-20 2016-02-24 因塞特控股公司 As the azetidinyl phenyl of JAK inhibitor, pyridyl or pyrazinyl carboxamides derivatives
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
IN2012CH01573A (en) 2012-04-20 2015-07-10 Advinus Therapeutics Ltd
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
HUE033294T2 (en) 2012-07-26 2017-11-28 Glaxo Group Ltd 2-(azaindol-2-yl)benzimidazoles as pad4 inhibitors
WO2014039714A2 (en) * 2012-09-06 2014-03-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CR20190073A (en) 2012-11-15 2019-04-25 Incyte Holdings Corp DOSAGE FORMS OF RUXOLITINIB OF SUSTAINED RELEASE (Divisional 2015-265)
RS62867B1 (en) 2013-03-06 2022-02-28 Incyte Holdings Corp Processes and intermediates for making a jak inhibitor
JP2016516710A (en) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド Pyridine CDK9 kinase inhibitor
CA2901929A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
CA2905935A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
UY35419A (en) 2013-03-14 2014-10-31 Abbvie Inc PIRROLO KINASA CDK9 INHIBITORS (2,3- B) PIRIDINE
CN105189512A (en) * 2013-03-14 2015-12-23 艾伯维公司 Pyrrolopyrimindine CDK9 kinase inhibitors
EP3030227B1 (en) 2013-08-07 2020-04-08 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
CN104804001B9 (en) * 2014-01-24 2022-02-08 江苏柯菲平医药股份有限公司 4-substituted pyrrolo [2,3-d ] pyrimidine compounds and uses thereof
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
WO2018165581A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
PE20211310A1 (en) 2018-01-30 2021-07-22 Incyte Corp PROCEDURE FOR THE ELABORATION OF A SOSA-CAL GLASS CONTAINER FROM 100% RECYCLED GLASS FORMING MATERIALS AND A GLASS CONTAINER MADE FROM SAID PROCEDURE
JP2021519775A (en) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Treatment of hidradenitis suppurativa with JAK inhibitors
CA3115472A1 (en) 2018-10-05 2020-04-09 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with apj receptor activity
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4275733B2 (en) * 1996-01-23 2009-06-10 ノバルティス アクチエンゲゼルシャフト Pyrrolopyrimidine and process for producing the same
EP0946554A1 (en) * 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
PA8474101A1 (en) * 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
ID26698A (en) * 1998-06-19 2001-02-01 Pfizer Prod Inc PIROLO COMPOUNDS [2,3-d] PYRIMIDINE
ES2253930T3 (en) * 1998-09-18 2006-06-01 ABBOTT GMBH & CO. KG 4-AMINOPIRROLOPIRIMIDINAS AS QUINASA INHIBITORS.
SK287188B6 (en) * 1999-12-10 2010-02-08 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compound, its use and pharmaceutical composition or combination containing the same

Also Published As

Publication number Publication date
ECSP034922A (en) 2004-04-28
JP4344607B2 (en) 2009-10-14
WO2003000695A8 (en) 2004-03-11
CN1518552A (en) 2004-08-04
AU2002314325B2 (en) 2009-01-08
SK15882003A3 (en) 2004-07-07
CZ20033443A3 (en) 2004-03-17
HUP0400300A2 (en) 2007-08-28
JP2005508300A (en) 2005-03-31
NZ529766A (en) 2008-11-28
TR200302242T2 (en) 2004-12-21
HUP0400300A3 (en) 2010-12-28
CA2451932A1 (en) 2003-01-03
AU2002314325B8 (en) 2009-01-29
CA2451932C (en) 2009-12-29
RS99203A (en) 2006-12-15
UA76760C2 (en) 2006-09-15
EA200400073A1 (en) 2004-08-26
OA12632A (en) 2006-06-14
PL374096A1 (en) 2005-09-19
CN1294135C (en) 2007-01-10
EE200400003A (en) 2004-02-16
TNSN03144A1 (en) 2005-12-23
EA007415B1 (en) 2006-10-27
GB0115393D0 (en) 2001-08-15
WO2003000695A1 (en) 2003-01-03
EE05432B1 (en) 2011-06-15
BR0210652A (en) 2004-08-10
MEP19308A (en) 2010-06-10
EP1404676A1 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
RS51698B (en) Pyrrolopyrimidines as protein kinase inhibitors
HRP20020547B1 (en) Azaindoles
AR036106A1 (en) SELECTIVE QUINASA INHIBITING AZAINDOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BRPI0509377A (en) alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1 receptor antagonists
BRPI9807222B8 (en) cetp activity inhibitor compounds, their uses and pharmaceutical compositions
HUP0204226A2 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
ATE287897T2 (en) ANALOGUE OF NUCLEOSIDES AND OLIGONUCLEOTIDES
DK0402644T3 (en) N- (Aryloxyalkyl) heteroaryl piperidines and heteroaryl piperazines, process for their preparation and their use as medicaments
BR0307409A (en) 2-Furanecarboxylic acid hydrazide compounds, pharmaceutical compositions containing them and use thereof for the preparation of a preventive or therapeutic agent
HRP20020109B1 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
BR0313297A (en) 6-alkoxy pyrido pyrimidines as p-38 map kinase inhibitors
CO5580747A2 (en) N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION
CO5540313A2 (en) PIRROLOPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA
AR038404A1 (en) USEFUL NICOTINAMIDE DERIVATIVES AS PDE4 INHIBITORS, PROCEDURE FOR THE PREPARATION OF THE COMPOUND AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
DE60105610D1 (en) Pyrazinonderivate
EA200100090A2 (en) New piperide-4-sulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them
AR046753A1 (en) BENZOXAZINE DERIVATIVES AND USES OF THE SAME
BRPI0414460A (en) carboxamide derivatives of the amide type, pharmaceutical composition and their use
AR011571A1 (en) A DERIVATIVE OF NAFTALENE, ITS USE, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND A PROCEDURE FOR ITS PREPARATION
RU2004130284A (en) ANTI-PARASITIC ARTEMISININ DERIVATIVES (ENDOPEROXIDES)
BR0312289A (en) Compound, pharmaceutical composition and use of a compound
DK0812838T3 (en) Pyridonecarboxylic acid derivatives substituted with bicyclic amino group, esters and salts thereof, and bicyclic amine as intermediate
AR026856A1 (en) AGONIST COMPOUNDS OF 5-HT1F AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME; PHARMACEUTICAL COMPOSITIONS FORMULATED WITH SUCH COMPOUNDS AND PROCEDURE TO INHIBIT THE EXTRAVASATION OF NEURONAL PROTEINS IN MAMMALS
DE69319900T2 (en) N, N'-DISUBSTITUTED AMIDE DERIVATIVES
DK1328277T3 (en) Bisphosphonic acid derivatives for cortical bone augmentation